Jump to content

Kevin Sabet Was Right?


slipstar059
 Share

Recommended Posts

Pharmaceutical cannabis is Genetically modified.  Just took a look at GW's Pharmacueticals Cultivation page, and they're definitely genetically modifying plants over there.

Breeding programme

GW's team includes experts in Cannabis breeding. In the genetic model used, the cannabinoid content of each chemical phenotype (chemotype) is controlled by four independent loci. By manipulating the genes at these four positions, our scientists can precisely control the cannabinoid composition of a plant. This is explained in the diagram below:

 

chemovars%5B0%5D.jpg

The gene at locus O allows the production of the initial phenolic precursors (resorcinolic acids). These combine with geranyl pyrophosphate to create the intermediate cannabinoids CBG and/or CBGV, the central precursors for the end-product cannabinoids THC(V), CBD(V) and CBC(V). The functional allele O is co-dominant; O/o hybrids have a low cannabinoid content and o/o plants are cannabinoid-free.

The ratio of propyl- and pentyl cannabinoid precursors is determined by a postulated locus A, which is still under investigation.

 

The CBG/CBGV intermediate is further processed by the alleles of locus B. BD and BT are co-dominant; the BD gene converts CBG(V) into CBD(V) and the BT gene converts CBG(V) into THC(V). In the BD/BT genotype, codominance allows the expression of a mixed CBD/THC chemotype. Also at this locus, non-functional alleles, designated B0 can exist; these are unable to convert the CBG(V) intermediate and leave the plant with a CBG(V) predominant chemotype.

 

Locus C is fixed so all plants have CBC synthase activity. CBC synthase competes for the same CBG(V) precursor as the synthases encoded by locus B (THC and/or CBD synthase). In 'normal' Cannabis plants, CBC synthase is only active in the juvenile state. However, our scientists have discovered genetic factors that induce morphological mutations that are associated with a 'prolonged juvenile chemotype'. Prototype CBC production plants carry these factors in combination with B0/B0 at locus B. In these plants CBC synthase has no competition from THC or CBD synthase.

Link to comment
Share on other sites

they are doing dna sequencing and dna testing to find out which plants produce the mutations required to harvest the specific cannabinoids. as far as i can tell from that page.

 

https://en.wikipedia.org/wiki/Locus_(genetics)

"By manipulating the genes at these four positions, our scientists can precisely control the cannabinoid composition of a plant."

There's a difference between mapping, and manipulating right? 

Link to comment
Share on other sites

unfortunately for them (and everyone really) there is no guidebook to the human body on how individual cannabinoids / terpenes will affect people.

 

they are going to have to run double blind placebo controlled tests on each cannabinoid and then each combination of cannibinoids. if the single magic bullet theory of medicine is to be followed.

Link to comment
Share on other sites

"By manipulating the genes at these four positions, our scientists can precisely control the cannabinoid composition of a plant."

There's a difference between mapping, and manipulating right?

it was my assumption that they mean manipulating those genes by breeding. maybe i am incorrect.

 

i mean "GW's team includes experts in Cannabis breeding."

 

is not "GW's team includes experts in genetic modification, gene manipulation and splicing".

Edited by t-pain
Link to comment
Share on other sites

And second of all,  kevin sabet is a twat.

I know that...  Do you remember the name of the book?  I'd like to check  it out. I'm reading Dr. David Potters thesis on propagation and Cannabis's use as a phytopharmacuetical, right now.  It's listed in their Research papers section, on their website.  There's are some really good papers, to peruse, here http://www.gwpharm.com/publications-1.aspxespecially if your trying to get a qualifying condition added to the list, through LARA.

Link to comment
Share on other sites

GW Pharma's main shareholder is Capital Research Developers, the main investor in CRD, is GILEAD,  The investors in GILEAD, include Vanguard, the main investor in Monsanto is Vanguard. So...

 

 

 Is this a 6 degrees of Kevin Bacon?

 

 

 

heh. I know what you are saying but I couldn't resist.

Link to comment
Share on other sites

 Is this a 6 degrees of Kevin Bacon?

 

 

 

heh. I know what you are saying but I couldn't resist.

More like 6 degree's, of a pile of money. ;)

Hopefully Monsanto, and it's investors, will do something positive with Cannabis (and I'm 100% serious here).  I don't care where they get it, there are people that seriously need help from this plant, and if they can normalize it here.  People won't have to live in fear, of taking their medicine. 

 

Link to comment
Share on other sites

Well, GW/Otsuka are about the pharmaceutical end. That is what medicine will likely be legalized if cannabis drops to schedule 2 or less.  Extracted uniformity are the only pharma that can pass the FDA approval.

 

Myself and I assume most here are directed towards an herbal medicine.

 

Both will hopefully exist.

Link to comment
Share on other sites

manipulations of genetic material is most definitely GMO tinkering. I bet without a GMO recorded sequence this company would not be able to patent this plant medicine.   we wanted our medicine, now we have to eat it too?

 

I posted op's info last year and it wasn't believed here. Maybe using todays non gmo organic cannabis, is making us smarter!

Edited by grassmatch
Link to comment
Share on other sites

GW started with selective breeding only.

 

 They would test 5000 plants(or more++) looking for specific genetic markers(refer to article) in plants to maximize certain appearances of alleles etc etc,... and selective bred and inbred to get their main lines.

 

Genetically Modified comes in if they have found a chemical to alter genetic codes to favour certain traits/feautures without the extensive breeding time.

Link to comment
Share on other sites

20090035396 Novel reference plant, a method for its production, extracts obtained therefrom and their use - The invention relates to a reference plant which has been selected to: 02-05-2009

http://www.faqs.org/patents/app/20090035396

 

It seems any use of the cannabis plant in medicine, has been applied for by GW.

 

http://www.faqs.org/patents/assignee/gw-pharma-limited/

     
 

GW PHARMA LIMITED GW PHARMA LIMITED Patent applications Patent application number Title Published 20150086653 PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER - This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon. 03-26-2015 20140378539 CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. 12-25-2014 20140377382 CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS - The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: 12-25-2014 20140296351 PHARMACEUTICAL FORMULATION - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. 10-02-2014 20140287067 ANTI-TUMOURAL EFFECTS OF CANNABINOID COMBINATIONS - The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). 09-25-2014 20140243405 A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD) - This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of 08-28-2014 20140221469 PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use. 08-07-2014 20140155456 USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY - The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate. 06-05-2014 20140107192 CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts. 04-17-2014 20140039043 PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIGEROL - The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders. 02-06-2014 20130296398 USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY - The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate. 11-07-2013 20130245110 USE FOR CANNABINOIDS - The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease. 09-19-2013 20130245109 PHARMACEUTICAL FORMULATION - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. 09-19-2013 20130109747 PHARMACEUTICAL FORMULATION 05-02-2013 20130059018 PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER - This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon. 03-07-2013 20130006182 PHARMACEUTICAL COMPOSITIONS - The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects. 01-03-2013 20120328718 PHARMACEUTICAL COMPOSITIONS - The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects. 12-27-2012 20120245224 CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts. 09-27-2012 20120225136 INHIBITION OF TUMOUR CELL MIGRATION - The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration. 09-06-2012 20120165402 USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY - This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD. 06-28-2012 20120059062 COMPOSITIONS COMPRISING CANNABINOIDS FOR TREATMENT OF NAUSEA, VOMITING, EMESIS, MOTION SICKNESS OR LIKE CONDITIONS - Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of 03-08-2012 20120004251 USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY - This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital. 01-05-2012 20110230549 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN - The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC. 09-22-2011 20110098348 CANNABIS SATIVA PLANTS RICH IN CANNABICHROMENE AND ITS ACID, EXTRACTS THEREOF AND METHODS OF OBTAINING EXTRACTS THEREFROM - The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a botanical drug substance (BDS) and a purified BDS; • A formulation comprising the BRM, BDS, purified BDS or other extract; • The use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; • A method of deriving plants yielding a high proportion of the cannabinoid CBC (A) at the expense of other cannabinoids; • A method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and • A method of extracting CBC(A) from said plants. 04-28-2011 20110082195 NEW USE FOR CANNABINOIDS - The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease. 04-07-2011 20110038958 USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT - The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication. 02-17-2011 20100323038 Pharmaceutical Compositions - The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects. 12-23-2010 20100317729 NEW PHARMACEUTICAL FORMULATION COMPRISING CANNABIDIOL AND TETRAHYDROCANNABIDIVARIN - The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB 12-16-2010 20100292345 THERAPEUTIC USES OF CANNABIGEROL - The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis. 11-18-2010 20100286098 USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease. 11-11-2010 20100249223 NEW USE FOR CANNABINOID-CONTAINING PLANT EXTRACTS - The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel. Preferably the diseases or conditions to be prevented or treated include neuropathic pain, inflammation or vasoconstriction. 09-30-2010 20100239693 CANNABINOID-CONTAINING PLANT EXTRACTS AS NEUROPROTECTIVE AGENTS - The invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration. In particular, the invention relates to use of one or more cannabinoid-containing plant extracts in the prevention or treatment of neural degeneration, wherein the one or more cannabinoid-containing plant extracts comprise: i) a cannabinoid-containing fraction; and ii) a non-cannabinoid containing fraction. 09-23-2010 20100196488 Pharmaceutical Formulation - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. 08-05-2010 20100168448 Methods of Preparing Cannabinoids From Plant Material - The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids. 07-01-2010 20100119606 PROCESSES AND APPARATUS FOR EXTRACTION OF ACTIVE SUBSTANCES AND ENRICHED EXTRACTS FROM NATURAL PRODUCTS - Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described. 05-13-2010 20100035978 COMBINATION OF CANNABINOIDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN - The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10. 02-11-2010 20100016418 Cannabinoids for use in the treatment of neuropathic pain - The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts. 01-21-2010 20090306221 Use for Cannabinoid - The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB 12-10-2009 20090035396 Novel reference plant, a method for its production, extracts obtained therefrom and their use - The invention relates to a reference plant which has been selected to: 02-05-2009 20080262099 Inhibition of Tumour Cell Migration - The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration. 10-23-2008

Link to comment
Share on other sites

It's also funny that people get so worked up about butane being used for extractions when they state they use it as a propellant.

 

The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects. 01

Link to comment
Share on other sites

The facts are that Big Pharma cant make any money if they cant patent it. They want to get in on the "pot" bandwagon for one reason only money.  When Big Pharma can patent MM then it will be legal  prescribed by mainstream doctors and paid for by insurance. If that requires GM MM then that's what they will do - its all about the money and always has been

Link to comment
Share on other sites

http://www.greenpeace.org/international/en/campaigns/agriculture/problem/genetic-engineering/ge-agriculture-and-genetic-pol/patents-on-life

 

Patents on Life

Biological diversity is undergoing a dangerous wave of privatisation under the label of "intellectual property rights," through the patenting of plants, animals, genes and smaller parts of DNA.

 

 

Patents are government guarantees that provide an inventor with exclusive rights to use, sell or manufacture an invention for a set period of time. A patent is usually granted for 20 years.

 

Patents should be granted only to human inventions, not discoveries. Existing living organisms - plants and animals as well as their genes - are no-one's invention and should therefore never be patented and put under private control.

 

However, over the past decades patents on plants and animals as well as genes and parts of human bodies have been repeatedly granted by the patent offices of industrialised countries.

 

Patenting of GE organisms allows industry to take control of and exploit common organisms and genetic material as exclusive private property that can be sold to or withheld from farmers, breeders, scientists and doctors. Technology agreements and fees on seeds, facilitated by patents, deprive farmers of their generations-old right to freely replant and exchange their seeds.

 

Vast, unsubstantiated patent claims on DNA also deter scientists from research in areas that have already been claimed by big companies with large legal budgets.

 

Why is it legal to patent genes?

 

Until recently, it was not possible to patent living organisms, which were always regarded as discoveries of nature and therefore unpatentable. In 1980, however, this all changed. In the landmark case of Diamond versus Chakrabarty, the US Supreme Court ruled that a living organism, a bacterium that could digest oil, could be patented.

 

Chief Justice Warren Burger declared that the "relevant distinction is not between animate and inanimate things but whether living products could be seen as human-made inventions". This extraordinary decision by the US Supreme Court heralded a new era in which living organisms could be patented, and paved the way for the enclosure of the biological commons.

 

Once a shared heritage, the gene pool of plants, animals and humans was now a commodity waiting to be bought and sold.

 

How does it work?

 

In what the industry calls 'bioprospecting' and others call 'biopiracy' scouts are sent to remote tropical areas to seek out valuable organisms or plants, often drawing upon the wisdom of indigenous peoples.

 

They then take samples back to laboratories where they isolate active ingredients or genetic sequences and patent them as their own inventions. Traditional knowledge systems and the people who have cultivated biodiversity over thousands of years count for less in patent law than routine laboratory procedures.

Communities could now end up having to pay multinational corporations for the right to use something that was previously part of their legacy.

 

Greenpeace opposes all patents on genes, plants, humans and parts of the human body and regards the biodiversity of this planet the common heritage of humankind.

 

For more information read: The True Cost of Gene Patents

http://www.greenpeace.org/international/PageFiles/24248/1Study_True_Costs_Gene_Patents.pdf

 

excerpt from PDF.

 

6
The negative consequences of gene patents described in this documentation can be
summarized as follows:
-
considerable increase in the burden on patients and health insurance funds
-
protracted litigation that may also severely impede research and development
-
a blockade of research and development by whole bundles of patents to be observed for
individual technical innovations
-
hindrance to medical institutions, particularly in the field of diagnosis
-
obstruction of current proteomics research
by hastily granted and too extensive gene
patents
-
impediment of research and development, particularly in the field of infectious diseases
-
unacceptable dependence of patients with hereditary diseases on individual companies
-
danger to world food supply owing to the exorbitant cost and monopolization of seeds
-
new systematic dependence of medium-sized plant breeders
-
considerable financial risks and direct dependence of farmers
-
stepping up of international concentration process in the seed industry
-
new dependence of food industry on agrochemistry
Edited by slipstar059
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
 Share

×
×
  • Create New...